Literature DB >> 1122183

Response of serum creatine phosphokinase to steroid hormone.

K Takahashi, M Oimomi, T Shinko, K Shutta, B Matsuo.   

Abstract

Serum creatine phosphokinase activity increased significantly four or six hours after the administration of prednisolone in patients with muscular dystrophy of various types, whereas it did not increase in other muscular disorders. The extent of the response correlated inversely with the grade of disability. The prednisolone test may help to differentiate muscular dystrophy from polymyositis.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1122183     DOI： 10.1001/archneur.1975.00490440039005

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


  4 in total

1.  Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Authors:  Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; William J Jusko; Panteleimon D Mavroudis; Benjamin D Schwartz; Laurel J Mengle-Gaw; Edward C Smith; Jean K Mah; Michela Guglieri; Yoram Nevo; Nancy Kuntz; Craig M McDonald; Mar Tulinius; Monique M Ryan; Richard Webster; Diana Castro; Richard S Finkel; Andrea L Smith; Lauren P Morgenroth; Adrienne Arrieta; Maya Shimony; Mark Jaros; Phil Shale; John M McCall; Yetrib Hathout; Kanneboyina Nagaraju; John van den Anker; Leanne M Ward; Alexandra Ahmet; Michaelyn R Cornish; Paula R Clemens
Journal:  Pharmacol Res       Date:  2018-09-13       Impact factor: 7.658

2.  Steroid-induced CPK estimation--a new diagnostic test for human muscular dystrophy and its carrier state.

Authors:  S Sen; P K Das
Journal:  Arch Dis Child       Date:  1978-06       Impact factor: 3.791

3.  Failure of the prednisolone test in neuromuscular disorders.

Authors:  G Vita; M Natoli; R Dattola; C Messina
Journal:  Ital J Neurol Sci       Date:  1982-07

4.  The effect of hydrocortisone on the serum creatine kinase activity of muscles diseases.

Authors:  K Cxyzewski
Journal:  J Neurol       Date:  1977-11-01       Impact factor: 4.849
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.